Formycon AG

Formycon ticked off all the important boxes in a “very reliable manner” last year, but 2025 greeted the German company with headwinds from the US market. In February, Formycon announced three major u

The six biosimilars to Johnson & Johnson ’s Stelara that have launched in the US have list prices 80% to 90% below the innovator’s wholesale acquisition cost, representing deeper discounts than t

The six biosimilars to Johnson & Johnson ’s Stelara that have launched in the US have list prices 80% to 90% below the innovator’s wholesale acquisition cost, representing deeper discounts than t

Sandoz management has set out more details of how it intends to reposition in the US market the Cimerli (ranibizumab-eqrn) biosimilar to Lucentis that it licenses from Formycon. In mid-February, Germa